HOLD MDLZ at 3% with hard stop at $58.44; symmetric risk/reward favors patient position through Q3 earnings catalyst
HOLD with discipline is the rational synthesis: the risk/reward is roughly symmetric at current configuration (10-15% upside if cocoa normalizes and Q3 prints margin recovery; 10-12% downside to $52-55 if 200 SMA breaks), the 3% sizing with hard stop at $58.44 limits residual portfolio risk to ~14bps, and the 3.39% dividend yields ~20bps during the 7-week hold to Q3 earnings. Neither the aggressive "lean in" thesis (23% growth is mechanical mean reversion still below 2022/2024 peaks) nor the defensive trim to 1-2% (internally incoherent with ballast thesis) survives scrutiny. Prior Underweight decisions came back as NaN alpha — a process failure not to be repeated. Q3 earnings (binary: gross margin recovery toward 32%+ or third consecutive 30-50bps compression) is the defined window during which the thesis either confirms or fails.
| Position | Action |
|---|---|
| Default allocation | Maintain 3% defensive ballast allocation |
| Close below $60.62 on volume >8M without breaking 200 SMA | Tighten stop to $59.50 |
| Confirmed close below $58.44 on volume >8M | Downgrade to Underweight; exit position |
| Confirmed close above $64.99 on volume >12M with MACD histogram flipping positive | Upgrade to Overweight |
MDLZ is a high-quality global compounder with iconic brands, disciplined capital return, and a normalizing input cost backdrop that makes the current entry point attractive for patient capital seeking the 23% forward earnings recovery already priced into consensus estimates.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $62.19 | bearish |
| 50 SMA | $61.51 | neutral |
| 200 SMA | $58.44 | bullish |
| RSI (14) | 43.83 | neutral |
| MACD | -0.03 | bearish |
| MACD Signal | 0.28 | bearish |
| MACD Histogram | -0.31 | bearish |
| VWMA (~20d) | $62.84 | bearish |
| Bollinger Middle | $62.73 | neutral |
| Bollinger Upper | $64.84 | neutral |
| Bollinger Lower | $60.62 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed close below $58.44 on volume >8M
Then: Exit position or reduce to 1-2%
↩ rebuts: “The stock is expensive at 22.6x trailing P/E”
EV: +5.1% to +9.8% · concedes: Poland's shrinkflation scrutiny represents a one-country regulatory review covering many food companies, though MDLZ has scale to manage SKU architecture across 80 countries; Iran geopolitical risk is a real tail risk affecting EM-wide exposure, not MDLZ-specific; MACD is in bearish crossover and RSI at 43.83 are real technical weaknesses; MACD bearish crossover and RSI at 43.83 are real data points that confirm near-term weakness; Goodwill of ~$44B from Cadbury/Kraft M&A results in negative tangible book value; EU packaging transition has capex costs despite future-proofing benefits
MDLZ's underperformance is structural, not cyclical; the risk/reward is symmetric or negative, not asymmetric to the upside; the margin recovery requires multiple uncertain variables to break right simultaneously; and better defensive alternatives exist elsewhere in the staples sector.
EV: ~ -0.5% to flat (probability-weighted) · concedes: Cocoa may normalize in 2026 (uncertain); MDLZ is indeed a defensive stock that should underperform growth indexes in isolation; Dividend yield of 3.39% is above Treasuries in absolute terms; Mildly Bullish sentiment suggests no extreme bearish positioning; 200 SMA at $58.44 provides some mechanical support
→ vs conservative: Goodwill of $44 billion at 170% of equity is not a ticking time bomb; it's the strategic IP portfolio of Cadbury, Oreo, Toblerone, Milka - brands that have printed money for decades
→ vs conservative: MDLZ underperformance versus S&P is not a sign of weakness but an opportunity - defensive laggards lead the next defensive rotation when growth cracks
→ vs neutral: MACD bearish cross and VWMA above spot are lagging indicators that tell what already happened, not what will happen; they ignore cocoa normalization and Q3 earnings catalysts
→ vs neutral: Waiting for confirmation above $64.99 on 12M shares means entering at $65-66+ rather than current levels, sacrificing the gift of current risk-defined entry
→ vs neutral: Reddit silence is not a warning flag - zero posts means no crowded pump-and-dump trade to unwind when institutional flow returns to staples
| bullish |
| ATR (14) | $1.32 (~2.2%) | neutral |
Support: 60.62 · 58.44 · 57.5 | Resistance: 62.73 · 64.84 · 64.99
MDLZ is in a short-term pullback within a structurally intact long-term uptrend, with price ($61.28) trading below all short- and medium-term averages while comfortably above the 200 SMA at $58.44. Momentum has rolled over with RSI at 43.83 and MACD bearish crossover confirmed (line at −0.03 below signal at 0.28), suggesting a neutral-to-bearish near-term stance. The stock is consolidating between the lower Bollinger band ($60.62) and middle ($62.73), with $58.44 as the critical trend-defining support level. Volume during the pullback (6–8M daily vs. 20.2M on the July breakout) indicates healthy correction, not trend collapse. The actionable bullish re-entry trigger is a close above $62.19 on volume >8M with RSI reclaiming 50; the bearish exit trigger is a daily close below the 200 SMA. ATR of $1.32 (~2.2% of price) supports orderly volatility and informs stop placement (tight $59.80, moderate $58.40, wide $57.50). The final transaction proposal is HOLD pending either the $62.19 reclaim or $58.44 breach.
Market Cap
$78.66 billion
P/E (TTM)
22.58x
Forward P/E
18.33x
PEG Ratio
0.91
P/B (Price/Book)
2.96x
EV/EBITDA
~12.9x
Dividend Yield
3.39%
52-Week High
$66.65
52-Week Low
$51.20
50-Day Average
$61.53
200-Day Average
$59.10
Beta
0.402
Book Value/Share
$20.80
Gross Profit
$12.36B
Gross Margin
31.1%
EBITDA
$6.08B
Operating Margin
21.98%
Net Profit Margin
8.86%
ROE
13.34%
ROA
4.12%
TTM EPS
$2.73
Forward EPS
$3.36
Revenue 2025
$38.54B
Revenue 2024
$36.44B
Revenue 2023
$36.04B
Revenue 2022
$31.50B
Revenue 2021
$31.50B
Net Income 2025
$2.45B
Net Income 2024
$4.96B
Diluted EPS 2025
$1.89
Diluted EPS 2024
$3.62
Revenue CAGR 5Y
~5.2%
Operating Cash Flow 2025
$4.51B
Capital Expenditure 2025
($1.28B)
Free Cash Flow 2025
$3.24B
FCF Conversion 2025
132%
Cash Dividends Paid 2025
$2.49B
Share Repurchases 2025
$2.39B
Cash & Equivalents 2025
$2.13B
Total Debt 2025
$21.80B
Net Debt 2025
$19.08B
Total Equity 2025
$25.84B
Total Assets 2025
$71.49B
Debt-to-Equity 2025
0.84x
Current Ratio 2025
0.60
Net Debt/EBITDA
~3.1x
Goodwill + Intangibles
$43.96B
Interest Expense 2025
$599M
Tax Rate 2025
25.9%
Cost of Revenue 2025
$27.6B
Operating Income 2025
$3.62B
International Revenue Exposure
~70%+
Strengths
Concerns
Mondelez International is a global confectionery and snack powerhouse with iconic brands (Oreo, Cadbury, Toblerone) trading at $78.66B market cap with a P/E of 22.58x and a defensive beta of 0.40. While FY2025 earnings collapsed 47% to $2.45B net income due to cocoa cost inflation, the company generated $3.24B in free cash flow (132% conversion) and returned $4.88B to shareholders via dividends ($2.49B) and buybacks ($2.39B). With a 3.39% dividend yield, PEG below 1.0 (0.91), and expected ~23% EPS recovery to $3.36, the risk/reward is favorable for a defensive compounder, though the $19.1B net debt load and $44B goodwill balance warrant monitoring.
Macro: Goldilocks-lite macro environment for global confectioner with 93% probability of zero Fed cuts in 2026 (high-for-longer rates supporting dividend appeal), only 8% probability of US recession by year-end 2026 (soft-landing intact, snack volumes stable), and 10% probability of inflation exceeding 4.5% (input cost tailwind for cocoa, sugar, dairy). Sugar costs slipping on smaller Indian imports. Key tail risk: Iran conflict escalation warning from Barron's/MT Newswires creating EM FX volatility and shipping/energy spike potential.